Thermo Fisher Scientific Inc. (TMO)
Exclusive: Thermo Fisher's plant making infant RSV drug breached FDA rules, documents show
One of the largest contract drug manufacturing plants in the U.S. owned by Thermo Fisher Scientific over the past 10 years has repeatedly breached rules meant to ensure drugs are free of contamination, FDA documents show, including twice this year.
Will Thermo Fisher (TMO) Beat Estimates Again in Its Next Earnings Report?
Thermo Fisher (TMO) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
TMO Stock Likely to Gain From New International CorEvitas AD Registry
Thermo Fisher launches international CorEvitas clinical registry in adolescent AD.
TMO Stock Gains From Innovation Amid Macroeconomic Issues
Thermo Fisher's business strategy involves expansion through strategic acquisition of technologies and businesses that boost its existing products and services.
TMO Stock to Gain From Expanded Bioanalytical Services in Sweden
Thermo Fisher's PPD arm unveils a new facility in Sweden, expanding its bioanalytical capabilities.
Thermo Fisher Scientific (TMO) presents at Morgan Stanley 22nd Annual Global Healthcare Conference - Conference Call Transcript
Thermo Fisher Scientific (NYSE:TMO ) Morgan Stanley 22nd Annual Global Healthcare Conference September 5, 2024 8:30 AM ET Company Participants Marc Casper - Chairman, President and CEO Conference Call Participants Tejas Savant - Morgan Stanley Tejas Savant Hey, everyone. Good morning.
Why Is Thermo Fisher (TMO) Up 1.6% Since Last Earnings Report?
Thermo Fisher (TMO) reported earnings 30 days ago. What's next for the stock?
Reasons to Retain Thermo Fisher (TMO) in Your Portfolio Now
Strategic alliances and impressive product launches bode well for Thermo Fisher (TMO).
Thermo Fisher's (TMO) CDx Gets FDA's Nod for Synovial Sarcoma
Thermo Fisher Scientific TMO recently secured FDA's 510(k) clearance for its SeCore CDx HLA A Sequencing System for use as a companion diagnostic (CDx) alongside Adaptimmune's ADAP newly approved T-cell receptor (TCR) therapy, TECELRA (afamitresgene autoleucel). The latter is the first engineered cell therapy for a solid tumor cancer approved in the United States and the first new therapy option in more than a decade for synovial sarcoma — a rare, soft tissue cancer that most commonly impacts young adults.
Thermo Fisher: A Dividend Investor's Lab Partner For Growth And Stability
Thermo Fisher Scientific is a top dividend growth stock with a complex post-pandemic situation. Recent earnings show promising growth in key segments, despite a high valuation. Strategic investments in R&D and acquisitions position TMO for continued long-term success.
3 Nanotechnology Stocks With Microscopic Risk
Given the expanding size of the nanotechnology industry, buying nanotechnology stocks with a very low-risk profile is possible. Electronics is one of the most important sectors that applies nanotechnology.
Thermo Fisher Scientific: Microscopic Signs Of Growth Emerging
Thermo Fisher Scientific is finally starting to show signs of growth after getting through the headwind of declining covid-related business. Growth sources include increased business in China, completion of the Olink deal, and an increase in the number of clinical trials. Financial model updates and valuation analysis suggest the stock is currently priced at fair value, making it a Hold for now.
